AstraZeneca has signed a deal worth up to $5.2bn to work with a Chinese biotech company using AI to develop new treatments for chronic diseases.

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival (PFS) in a phase 3 breast ...

Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of scheming to delay a generic version of its schizophrenia drug Seroquel ...

AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He’d like it to be higher.

The pharmaceutical drug company AstraZeneca filed a lawsuit against the Utah attorney general claiming Utah's new law on limiting prescription drug prices goes against a federal program.

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to results from a phase 3 study. Adding Imfinzi to the chemotherapy regimen ...

Astra has agreed a deal that could be worth almost £4billion with a Chinese company to use AI in the production of new treatments for chronic diseases.

AstraZeneca welcomed NICE’s decision, which expands access beyond previous eligibility criteria set in 2022. It aligns with a recent acceptance by the Scottish Medicines Consortium (SMC) for the same ...

At ASCO Day 3, AstraZeneca dominates, Takeda reveals experimental drug data, Eli Lilly serves salad. The SERD spectacle, the VERIFY study, and the dream of a better multi-cancer liquid biopsy test.

Danaher Corporation DHR recently partnered with AstraZeneca PLC AZN to develop and market novel diagnostic tools aimed at improving patient selection for precision medicine treatments. Based in ...

AstraZeneca CEO Pascal Soriot unpacks President Donald Trump's drug cost cut executive order on 'The Claman Countdown.' Fox Business Posted: June 4, 2025 | Last updated: June 4, 2025 ...

AstraZeneca Pharma shares rose nearly 12 per cent after the company posted strong Q4 results. Profit jumped 48 per cent and revenue increased by 25 per cent. Growth came from cancer, heart, and ...